GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.
Merck is discontinuing development of MK-7710 (formerly known as CD24Fc), a Phase III Covid-19 therapeutic asset acquired from OncoImmune during November 2020.
The U.S. Centers for Disease Control and Prevention (CDC) said up to 5,800 people who have been fully vaccinated against coronavirus disease 2019 have been infected by the novel coronavirus following vaccination.
There is a much higher risk of brain blood clots from Covid-19 infection than there is from vaccines against the disease, British researchers said on April 15, after the rollout of inoculations was disrupted by reports of rare clots.
None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.
Thermo Fisher Scientific Inc. is acquiring contract researcher PPD Inc. for $17.4 billion as the medical device maker adds more muscle to the company’s pharmaceutical services business.
The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China
AstraZeneca Plc said on April 14 that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.
The U.S. Food and Drug Administration granted vTv Therapeutics’ TTP399 Breakthrough Therapy designation for type 1 diabetes.
